GAS5 and acute lymphoblastic leukemia: DCA curves clearly demonstrated the superior clinical net benefit of multivariate models incorporating blasts’ GAS5 overexpression at disease diagnosis for the prognosis of both OS (Figure 5A) and DFS (Figure 5B) post-treatment outcome, compared to the “control” models of the established clinical markers of patients’ age, WBC, prednisone response (day 8), bone marrow (day15), MRD (day15) and ALL-BFM risk group, from low threshold probabilities <10%.